Covalent screening has become a powerful strategy in modern small-molecule drug discovery, enabling researchers to tackle targets that are often difficult to address using traditional approaches. Once viewed as high risk, covalent strategies are now widely recognized for their ability to deliver potent, selective, and long-lasting therapeutics.
Unlike conventional screening methods, covalent approaches rely on more than transient binding interactions. They require a carefully tuned balance between reversible target recognition and covalent bond…

Drug discovery doesn’t sleep, and neither does our SPR (Surface Plasmon Resonance) team. While the Assay Group takes a well-deserved weekend break and goes for dinner tonight, our relentless SPR team is tirelessly screening compounds, revealing critical insights that help drive discovery forward. 
Meet the Team:
Each of our SPR machines brings unique strengths to the lab, earning their names and personalities for how they support our research. These workhorses are the true heroes of our lab, capturing precise data…

Molecular glues have emerged as an exciting new class of agents in drug discovery, offering a novel mechanism to modulate protein function, both as protein degraders and for other therapeutic targets. Unlike traditional drugs that inhibit or block protein activity, molecular glues enhance or induce new protein-protein interactions (PPIs), allowing them to activate biological pathways rather than suppressing them. For instance, the natural compound Rapamycin has been used as an immunosuppressant for decades. It binds at the interface of mTOR and FKBP12 and increases the interaction between these two proteins…